These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 10568893)

  • 1. Development of an FDA guidance document for clinical trials in SLE.
    Siegel JN
    Lupus; 1999; 8(8):581-5. PubMed ID: 10568893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A lupus drug and FDA approval.
    Merrill JT; Raymond S
    Science; 2005 Apr; 308(5721):497; author reply 497. PubMed ID: 15845832
    [No Abstract]   [Full Text] [Related]  

  • 3. Drug development. Lupus drug company asks FDA for second chance.
    Couzin J
    Science; 2005 Feb; 307(5711):835. PubMed ID: 15705822
    [No Abstract]   [Full Text] [Related]  

  • 4. Improved strategies for designing lupus trials with targeted therapies: learning from 65 years of experience.
    Wallace DJ
    Lupus; 2016 Sep; 25(10):1141-9. PubMed ID: 27497258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDA slow to encourage lupus drugs.
    Webber D
    Nat Biotechnol; 1999 Apr; 17(4):319. PubMed ID: 10207867
    [No Abstract]   [Full Text] [Related]  

  • 6. Advances in drug therapy for systemic lupus erythematosus.
    Wallace DJ
    BMC Med; 2010 Nov; 8():77. PubMed ID: 21114845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Belimumab: review of use in systemic lupus erythematosus.
    Boyce EG; Fusco BE
    Clin Ther; 2012 May; 34(5):1006-22. PubMed ID: 22464040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A critical review of clinical trials in systemic lupus erythematosus.
    Mahieu MA; Strand V; Simon LS; Lipsky PE; Ramsey-Goldman R
    Lupus; 2016 Sep; 25(10):1122-40. PubMed ID: 27497257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EULAR points to consider for conducting clinical trials in systemic lupus erythematosus.
    Gordon C; Bertsias G; Ioannidis JP; Boletis J; Bombardieri S; Cervera R; Dostál C; Font J; Gilboe IM; Houssiau F; Huizinga TW; Isenberg D; Kallenberg CG; Khamashta MA; Piette JC; Schneider M; Smolen JS; Sturfelt G; Tincani A; Van Vollenhoven R; Boumpas DT
    Ann Rheum Dis; 2009 Apr; 68(4):470-6. PubMed ID: 18388158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Re-evaluating ethical concerns in planned emergency research involving critically ill patients: an interpretation of the guidance document from the United States Food and Drug Administration.
    Smischney NJ; Onigkeit JA; Hinds RF; Nicholson WT
    J Clin Ethics; 2015; 26(1):61-7. PubMed ID: 25794295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. International Conference on Harmonisation; choice of control group and related issues in clinical trials; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2001 May; 66(93):24390-1. PubMed ID: 12356096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Research misconduct identified by the US Food and Drug Administration: out of sight, out of mind, out of the peer-reviewed literature.
    Seife C
    JAMA Intern Med; 2015 Apr; 175(4):567-77. PubMed ID: 25664866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Innovations in the pharmaceutical treatment of systemic lupus erythematosus].
    Mucke J; Schneider M
    Internist (Berl); 2022 May; 63(5):566-572. PubMed ID: 35059768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of systemic lupus erythematosus: myths, certainties and doubts].
    Ruiz-Irastorza G; Danza A; Khamashta M
    Med Clin (Barc); 2013 Dec; 141(12):533-42. PubMed ID: 23622892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statistical considerations for stopping systemic lupus erythematosus clinical trials earlier.
    Lew RA; Liang MH; Doros G
    Arthritis Res Ther; 2015 Dec; 17():345. PubMed ID: 26634344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of FDA and EMEA guidelines on drug development in relation to Phase 0 trials.
    Marchetti S; Schellens JH
    Br J Cancer; 2007 Sep; 97(5):577-81. PubMed ID: 17726450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mycophenolate mofetil in the treatment of systemic lupus erythematosus.
    Dall'Era M
    Curr Opin Rheumatol; 2011 Sep; 23(5):454-8. PubMed ID: 21720247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. US FDA patient-reported outcome guidance: great expectations and unintended consequences.
    Fehnel S; DeMuro C; McLeod L; Coon C; Gnanasakthy A
    Expert Rev Pharmacoecon Outcomes Res; 2013 Aug; 13(4):441-6. PubMed ID: 23977972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents.
    Dancey JE; Dobbin KK; Groshen S; Jessup JM; Hruszkewycz AH; Koehler M; Parchment R; Ratain MJ; Shankar LK; Stadler WM; True LD; Gravell A; Grever MR;
    Clin Cancer Res; 2010 Mar; 16(6):1745-55. PubMed ID: 20215558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Belimumab: a BLyS-specific inhibitor for systemic lupus erythematosus.
    Wiglesworth AK; Ennis KM; Kockler DR
    Ann Pharmacother; 2010 Dec; 44(12):1955-61. PubMed ID: 21081710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.